CA-CROWN-BIOSCIENCE
7.10.2021 14:32:07 CEST | Business Wire | Press release
Crown Bioscience, a JSR Life Sciences company and leader in translational services that help biopharmaceutical companies accelerate new drug development programs, today announced the launch of its ‘3D Ex Vivo Patient Tissue Platform’. Using freshly collected patient tumor material, this new service can accurately measure oncology and immuno-oncology drug-induced tumor killing and endogenous immune cell proliferation in a high throughput format. Researchers are presenting data on the new platform at this year’s AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics , which is happening virtually on October 7-10, 2021.
The proprietary technology, developed at Crown Bioscience’s recently acquired site in Leiden, The Netherlands (formerly known as OcellO B.V.), aims to improve clinical success rates by using the most patient-relevant tumor samples to better predict tumor response to potential drug candidates.
“Our goal is to leverage our core technologies to build a translational model system that adequately captures the tumor architecture and microenvironment, and improves the predictability of patient responses to treatment protocols for existing and potential therapeutic candidates,” said Leo Price, PhD, Senior Vice President, In Vitro . “We believe this approach provides greater translational relevance in drug development by using immuno-competent primary human tumor tissue to help analyze drug candidate responses before the program enters clinical trial. This approach is an optimal fit with our mission to help deliver the right drug to the right patient at the right time.”
The ‘3D Ex Vivo Patient Tissue Platform’ utilizes patient tumor tissue isolated from biopsies, surgical resections, ascites, or pleural effusion samples that are processed within 24 hours to preserve the tumor microenvironment. The automated high throughput platform uses high content 3D imaging and image analysis to quantify distinct responses of individual cell populations in fresh patient tissues. These analyses can assess responses to different doses of therapeutic candidates at various timepoints and can determine the effects of the drug or combination of drugs on tumor killing and immune cell proliferation.
“We believe this new service can help fill a critical gap in today’s research landscape with early translational patient-relevant ex vivo models that can assess efficacy and determine mechanisms of action,” commented Armin Spura, PhD, Chief Executive Officer of Crown Bioscience . “This new service offering is designed to help mitigate the high failure rates of clinical programs in oncology, and was one of the objectives coming out of our recent OcellO acquisition. We are delighted to provide immediate value to our customers from this investment and look forward to the future value that this acquisition will bring.”
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Researchers from CrownBio are conducting a poster presentation titled, “Novel Near Vivo Drug Response Platform for Oncology using 3D Ex Vivo Patient-Derived Microtumors” at the annual conference. The poster summarizes:
- This 3D high content assay on ex vivo patient tumor material preserves native tumor microenvironement and architecture
- Ex vivo testing using ultra fresh patient tumor samples maintains intact endogenous immune cell populations
- Ongoing clinical trial collaborations with tissue providers for ovarian cancer, bladder cancer, NSCLC, and other tumor samples
For more information on Crown Bioscience’s 3D Ex Vivo Patient Tissue Platform, visit Crown Bioscienes's webpage on the new service.
###
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development services company providing translational platforms to advance oncology, immuno-oncology, and immune mediated inflammatory disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211007005565/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tigo Energy Builds on 80MW of C&I Solar Growth in Czechia with GO Optimized ESS for Residential1.10.2026 06:00:00 CEST | Press release
Strong commercial solar market performance in Czechia and installer trust in solar hardware provide a foundation for Tigo GO Optimized ESS showcase at Smart Energy Forum 2026 in Prague. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that the Company will showcase the Tigo GO Optimized Energy Storage Solution (ESS) at Smart Energy Forum (SEF) 2026 in Prague, building on strong adoption of Tigo technology across the Czech commercial and industrial (C&I) solar market. Since 2024, Czech installers have deployed Tigo products in approximately 80MW of C&I systems, providing a solid foundation for Tigo to expand its residential solar-plus-storage offering. Across residential, small commercial, and larger C&I applications, installers in Czechia have deployed approximately 276MW of Tigo systems since 2024. At the heart of the Tigo showcase will be the Tigo GO Optimized ESS, featuring the expanded sto
Umios and Wah Kong Complete Strategic Pet Food Joint Venture in Southeast Asia; Japan Corporate Advisory Institute Advised on the Transaction1.10.2026 02:00:00 CEST | Press release
JPY 11.4 billion investment establishes strategic partnership around Pet World International and accelerates Umios’s Asia strategy Umios Corporation (TOKYO Prime: 1333; formerly Maruha Nichiro) and Wah Kong Corporation have completed the establishment of a strategic joint venture centered on Pet World International Sdn. Bhd. (“PWI”), one of Malaysia’s leading pet food companies. Under the transaction, Umios invested approximately JPY 11.4 billion to acquire a 51% interest in PWI through a newly established holding company. PWI holds the No. 2 share of Malaysia’s pet food market — No. 1 among local companies (NielsenIQ) — and operates the country’s only BRC-certified pet food plant. The company has approximately 350 employees, sells through more than 10,000 physical stores and its own e-commerce channels, and posted consolidated sales of approximately JPY 12.4 billion in the year ended September 2025. The joint venture combines Umios’s strengths in wet pet food with PWI’s dry-food capab
INNIO Completes Acquisition of Enerflex APAC Aftermarket Operations30.9.2026 23:02:00 CEST | Press release
INNIO N.V. (Nasdaq: INIO) today announced the completion of its acquisition of Enerflex Ltd.’s aftermarket business operations in Australia, Thailand, and Indonesia. The transaction strengthens INNIO’s presence in the Asia-Pacific (APAC) region and expands its ability to serve customers through enhanced local service capabilities and greater customer proximity. The acquired business operates principally across three countries and eight locations and brings extensive workshop and office facilities, a highly experienced workforce, and a strong installed base supported by long-term service agreements with major oil and gas companies in the region. Through the transaction, INNIO further strengthens its ability to deliver responsive, high-quality service and lifecycle support to customers throughout APAC. Forward-Looking Statements This press release includes forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Textron Aviation Builds Future Workforce With Kansas’ First Aviation Youth Apprenticeship Program.30.9.2026 20:55:00 CEST | Press release
By combining education and industry experience, the new program creates early career opportunities for high school students while strengthening Kansas’ aviation workforce Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, is further bolstering the company’s efforts to build the next generation workforce as the first aviation company in Kansas to offer state-registered youth apprenticeships through the Kansas Office of Apprenticeships. The program expands career opportunities for high school students beginning at age 16 by providing paid, hands-on learning experiences that develop industry knowledge and career-ready skills while they complete their education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260930818829/en/ Textron Aviation builds future workforce with Kansas’ first aviation youth apprenticeship program (Photo Credit: Textron Aviation). Textron Aviation is launching three state-registered youth apprenti
Thales and Landis+Gyr Enable Smarter, Remotely Managed Connectivity for Smart Meter Fleets30.9.2026 20:00:00 CEST | Press release
Thales, a global leader in cybersecurity and IoT connectivity management, and Landis+Gyr, a global energy technology leader grid edge intelligence and energy management, today announced a strategic collaboration to enable secure, scalable and future-ready cellular connectivity for smart meter deployments across North America. Thales will provide Landis+Gyr with eSIM technology and advanced IoT connectivity management to support the digital transformation of utilities by simplifying and securing remote management of smart meter fleets throughout their entire lifecycle. The solution - combined with Simetric’s single pane of glass - gives utilities a unified view of connectivity operations across their devices, enabling centralized monitoring and control of large-scale deployments to reduce field interventions and improve operational efficiency globally. As utilities modernize their infrastructure, smart meters are becoming an increasingly important part of the connected energy ecosystem.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom